Latest & greatest articles for breast cancer screening

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer screening or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer screening

21. [Invitation and decision guide for breast cancer screening]

[Invitation and decision guide for breast cancer screening] Einladungsschreiben und entscheidungshilfe zum mammographie-screening: abschlussbericht; auftrag P14-0 [Invitation and decision guide for breast cancer screening] Einladungsschreiben und entscheidungshilfe zum mammographie-screening: abschlussbericht; auftrag P14-0 [Invitation and decision guide for breast cancer screening] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Einladungsschreiben und entscheidungshilfe zum mammographie-screening: abschlussbericht; auftrag P14-0. [Invitation and decision guide for breast cancer screening] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG

Health Technology Assessment (HTA) Database.2017

22. Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening in Women at Less Than High Risk for Breast Cancer

Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening in Women at Less Than High Risk for Breast Cancer Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening in Women at Less Than High Risk for Breast Cancer - Health Quality Ontario (HQO) Let's make our health system healthier Open Menu Quick Links Loading Loading A A A Evidence to Improve Care Share: Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening (...) in Women at Less Than High Risk for Breast Cancer Ontario Health Technology Advisory Committee Recommendation The Ontario Health Technology Advisory Committee recommends against publicly funding screening breast magnetic resonance imaging (MRI) as an adjunct to screening mammography for women who are at less than high risk for breast cancer and who have no personal history of breast cancer Breast cancer is the most common cancer among Canadian women. The most common form of screening for breast cancer

Health Quality Ontario2017

23. Developing a Breast Cancer Screening Program in Nigeria: Evaluating Current Practices, Perceptions, and Possible Barriers

Developing a Breast Cancer Screening Program in Nigeria: Evaluating Current Practices, Perceptions, and Possible Barriers 29094087 2018 11 13 2378-9506 3 5 2017 Oct Journal of global oncology J Glob Oncol Developing a Breast Cancer Screening Program in Nigeria: Evaluating Current Practices, Perceptions, and Possible Barriers. 490-496 10.1200/JGO.2016.007641 In low- and middle-income countries like Nigeria, women present with advanced breast cancer at an earlier age. Given the limited resources (...) , development of screening programs that parallel resource capabilities of low- and middle-income countries is imperative. The objective of this study was to evaluate the perceptions, practices, and barriers regarding clinical breast examination (CBE) screening in a low-income community in Nigeria. A cross-sectional survey of women age 40 years or older in Ife, Nigeria, using multistaged sampling was performed. Information on sociodemographics, knowledge of breast cancer, screening practices

Journal of global oncology2017 Full Text: Link to full Text with Trip Pro

24. Breast Cancer Screening in Denmark: A Cohort Study of Tumor Size and Overdiagnosis.

Breast Cancer Screening in Denmark: A Cohort Study of Tumor Size and Overdiagnosis. Background: Effective breast cancer screening should detect early-stage cancer and prevent advanced disease. Objective: To assess the association between screening and the size of detected tumors and to estimate overdiagnosis (detection of tumors that would not become clinically relevant). Design: Cohort study. Setting: Denmark from 1980 to 2010. Participants: Women aged 35 to 84 years. Intervention: Screening (...) programs offering biennial mammography for women aged 50 to 69 years beginning in different regions at different times. Measurements: Trends in the incidence of advanced (>20 mm) and nonadvanced (≤20 mm) breast cancer tumors in screened and nonscreened women were measured. Two approaches were used to estimate the amount of overdiagnosis: comparing the incidence of advanced and nonadvanced tumors among women aged 50 to 84 years in screening and nonscreening areas; and comparing the incidence

Annals of Internal Medicine2017

25. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).

Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). BACKGROUND: Women genetically predisposed to breast cancer often develop the disease at a young age when dense breast tissue reduces the sensitivity of X-ray mammography. Our aim was, therefore, to compare contrast enhanced magnetic resonance imaging (CE MRI) with mammography for screening. METHODS: We did a prospective multicentre (...) cohort study in 649 women aged 35-49 years with a strong family history of breast cancer or a high probability of a BRCA1, BRCA2, or TP53 mutation. We recruited participants from 22 centres in the UK, and offered the women annual screening with CE MRI and mammography for 2-7 years. FINDINGS: We diagnosed 35 cancers in the 649 women screened with both mammography and CE MRI (1881 screens): 19 by CE MRI only, six by mammography only, and eight by both, with two interval cases. Sensitivity

Lancet2017

26. Breast Cancer Risk Assessment and Screening in Average-Risk Women

Breast Cancer Risk Assessment and Screening in Average-Risk Women Breast Cancer Risk Assessment and Screening in Average-Risk Women - ACOG Menu ▼ Breast Cancer Risk Assessment and Screening in Average-Risk Women Page Navigation ▼ Number 179, July 2017 (Replaces Practice Bulletin Number 122, August 2011) Committee on Practice Bulletins—Gynecology. This Practice Bulletin was developed by the Committee on Practice Bulletins—Gynecology in collaboration with Mark Pearlman, MD; Myrlene Jeudy, MD (...) presented. Breast Cancer Risk Assessment and Screening in Average-Risk Women Breast cancer is the most commonly diagnosed cancer in women in the United States and the second leading cause of cancer death in American women ( ). Regular screening mammography starting at age 40 years reduces breast cancer mortality in average-risk women ( ). Screening, however, also exposes women to harm through false-positive test results and overdiagnosis of biologically indolent lesions. Differences in balancing

American College of Obstetricians and Gynecologists2017

27. Breast Cancer Screening

Breast Cancer Screening Revised 2017 ACR Appropriateness Criteria ® 1 Breast Cancer Screening American College of Radiology ACR Appropriateness Criteria ® Breast Cancer Screening Variant 1: Breast cancer screening. Average-risk women: women with <15% lifetime risk of breast cancer. Procedure Appropriateness Category Relative Radiation Level Mammography screening Usually Appropriate ?? Digital breast tomosynthesis screening Usually Appropriate ?? US breast May Be Appropriate O MRI breast without (...) and with IV contrast Usually Not Appropriate O MRI breast without IV contrast Usually Not Appropriate O FDG-PEM Usually Not Appropriate ???? Tc-99m sestamibi MBI Usually Not Appropriate ??? Variant 2: Breast cancer screening. Intermediate-risk women: women with personal history of breast cancer, lobular neoplasia, atypical ductal hyperplasia, or 15% to 20% lifetime risk of breast cancer. Procedure Appropriateness Category Relative Radiation Level Mammography screening Usually Appropriate ?? Digital breast

American College of Radiology2017

28. Breast Cancer Screening

Breast Cancer Screening © 1996 Kaiser Foundation Health Plan of Washington. All rights reserved. 1 Breast Cancer Risk Assessment and Screening Guideline Major Changes as of September 2017 2 Background and Principles 2 Risk Assessment 3 Screening Recommendations Based on Risk Assessment 4 Shared Decision Making for Women at Average Risk 5 Screening Tests and Exams 7 Referral to Genetics or Oncology 8 Evidence Summary and References 8 Guideline Development Process and Team 9 Appendix 1. Breast (...) guideline. 2 Major Changes as of September 2017 • The 2017 guideline update emphasizes early identification of women at high risk for breast cancer. • Risk screening questions are asked of women at regular intervals starting at age 18 and continuing through age 74. The results are used to guide screening decisions, including screening interval and age to begin screening. • The Bellcross tool has been replaced by the expansion of risk screening questions in: o Online Health Profile—completed prior

Kaiser Permanente Clinical Guidelines2017

30. Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women atless than high risk for breast cancer: a health technology assessment

Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women atless than high risk for breast cancer: a health technology assessment Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: a health technology assessment Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: a health technology assessment (...) Health Quality Ontario Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Health Quality Ontario. Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: a health technology assessment. Toronto: Health Quality Ontario (HQO). Ontario health technology assessment series

Health Technology Assessment (HTA) Database.2017

31. Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: OHTAC recommendation

Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: OHTAC recommendation Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: OHTAC recommendation Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: OHTAC recommendation Health Quality Ontario Record (...) Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Health Quality Ontario. Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: OHTAC recommendation. Toronto: Health Quality Ontario (HQO). 2016 Authors' conclusions The Ontario Health Technology Advisory Committee (OHTAC

Health Technology Assessment (HTA) Database.2017

33. Digital breast tomosynthesis for breast cancer diagnosis and screening

Digital breast tomosynthesis for breast cancer diagnosis and screening Digital breast tomosynthesis for breast cancer diagnosis and screening Digital breast tomosynthesis for breast cancer diagnosis and screening HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Digital breast tomosynthesis for breast cancer diagnosis and screening. Lansdale (...) , particularly when compared with modifications of digital mammography that involve spot compression and magnified and angled views. Key Questions: Does digital breast tomosynthesis (DBT) provide a more accurate diagnosis than conventional mammography in women with symptoms or suspicious breast lesions? Does DBT reduce the recall and biopsy rates and the rates of breast cancer morbidity and mortality in asymptomatic women who undergo routine screening with this test? Does information obtained with DBT

Health Technology Assessment (HTA) Database.2017

34. Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening in Women at Less Than High Risk for Breast Cancer

Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening in Women at Less Than High Risk for Breast Cancer Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening in Women at Less Than High Risk for Breast Cancer - Health Quality Ontario (HQO) Let's make our health system healthier Open Menu Quick Links Loading Loading A A A Evidence to Improve Care Share: Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening (...) in Women at Less Than High Risk for Breast Cancer Ontario Health Technology Advisory Committee Recommendation The Ontario Health Technology Advisory Committee recommends against publicly funding screening breast magnetic resonance imaging (MRI) as an adjunct to screening mammography for women who are at less than high risk for breast cancer and who have no personal history of breast cancer Breast cancer is the most common cancer among Canadian women. The most common form of screening for breast cancer

Health Quality Ontario2016

35. Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness.

Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness. BACKGROUND: The goal of screening mammography is to detect small malignant tumors before they grow large enough to cause symptoms. Effective screening should therefore lead to the detection of a greater number of small tumors, followed by fewer large tumors over time. METHODS: We used data from the Surveillance, Epidemiology, and End Results (SEER) program, 1975 through 2012, to calculate the tumor-size (...) distribution and size-specific incidence of breast cancer among women 40 years of age or older. We then calculated the size-specific cancer case fatality rate for two time periods: a baseline period before the implementation of widespread screening mammography (1975 through 1979) and a period encompassing the most recent years for which 10 years of follow-up data were available (2000 through 2002). RESULTS: After the advent of screening mammography, the proportion of detected breast tumors that were small

NEJM2016

36. Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study

Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics:a dual cohort study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could (...) not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} The study found that risk precision in breast cancer can be improved by using information from deoxyribonucleic acid and mammographic breast density, and could be used to stratify screening in the NHS Breast Screening Programme. It may also identify women at greater risk of high-stage cancers

NIHR HTA programme2016 Full Text: Link to full Text with Trip Pro

37. Women's experiences of inaccurate breast cancer screening results: a systematic review and qualitative meta-synthesis

Women's experiences of inaccurate breast cancer screening results: a systematic review and qualitative meta-synthesis Women's experiences of inaccurate breast cancer screening results: a systematic review and qualitative meta-synthesis Women's experiences of inaccurate breast cancer screening results: a systematic review and qualitative meta-synthesis Health Quality Ontario Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation Health Quality Ontario. Women's experiences of inaccurate breast cancer screening results: a systematic review and qualitative meta-synthesis. Toronto: Health Quality Ontario (HQO). Ontario health technology assessment series; 16(16). 2016 Authors' conclusions Qualitative studies provide some insight into how breast cancer screening inaccuracy affects women, including their faith in the screening technology

Health Technology Assessment (HTA) Database.2016

38. Ultrasound as an adjunct to mammography for breast cancer screening: OHTAC recommendation

Ultrasound as an adjunct to mammography for breast cancer screening: OHTAC recommendation Ultrasound as an adjunct to mammography for breast cancer screening: OHTAC recommendation Ultrasound as an adjunct to mammography for breast cancer screening: OHTAC recommendation Health Quality Ontario Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) Health Quality Ontario. Ultrasound as an adjunct to mammography for breast cancer screening: OHTAC recommendation. Toronto: Health Quality Ontario (HQO). 2016 Authors' conclusions The Ontario Health Technology Advisory Committee recommends publicly funding screening breast ultrasound as an adjunct to screening mammography for high-risk women in whom magnetic resonance imaging (MRI) is contraindicated. The Ontario Health Technology Advisory Committee recommends against publicly funding screening

Health Technology Assessment (HTA) Database.2016

39. Ultrasound as an adjunct to mammography for breast cancer screening: a health technology assessment

Ultrasound as an adjunct to mammography for breast cancer screening: a health technology assessment Ultrasound as an adjunct to mammography for breast cancer screening: a health technology assessment Ultrasound as an adjunct to mammography for breast cancer screening: a health technology assessment Health Quality Ontario Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Health Quality Ontario. Ultrasound as an adjunct to mammography for breast cancer screening: a health technology assessment. Toronto: Health Quality Ontario (HQO). Ontario health technology assessment series; 16(15). 2016 Authors' conclusions We found no evidence that evaluated the comparative effectiveness or diagnostic accuracy of screening breast ultrasound as an adjunct to mammography among average-risk women aged 50 years and over. In women at high risk of developing

Health Technology Assessment (HTA) Database.2016

40. Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes.

Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes. Background: Biennial screening is generally recommended for average-risk women aged 50 to 74 years, but tailored screening may provide greater benefits. Objective: To estimate outcomes for various screening intervals after age 50 years based on breast density and risk for breast cancer. Design: Collaborative simulation modeling using national (...) incidence, breast density, and screening performance data. Setting: United States. Patients: Women aged 50 years or older with various combinations of breast density and relative risk (RR) of 1.0, 1.3, 2.0, or 4.0. Intervention: Annual, biennial, or triennial digital mammography screening from ages 50 to 74 years (vs. no screening) and ages 65 to 74 years (vs. biennial digital mammography from ages 50 to 64 years). Measurements: Lifetime breast cancer deaths, life expectancy and quality-adjusted life

Annals of Internal Medicine2016 Full Text: Link to full Text with Trip Pro